International Journal of Pharmaceutical Drug Design
IJPDD, Vol.-1, Issue-6 (May, 2024)
ISSN: 2584-2897
Website: https://ijpdd.org/

Review

Targeting Apoptotic Cell Death in Cancer Therapy: Chemotherapeutic Approaches

Nagendra Singh*, Preeti Anand, Km. Bhumika

Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, 250001, U.P., India

Article History
Received: 24/04/2024
Revised : 15/05/2024
Accepted : 24/05/2024

DOI:
10.62896/ijpdd.1.6.10

Abstract:
One of the main goals of contemporary oncological research is to generate more potent and less harmful medicines by focusing on apoptotic cell death in cancer therapy. This review article offers a thorough summary of chemotherapeutic strategies targeted at causing cancer cells to undergo apoptosis. It starts off by going over what is now known about apoptosis, including how it affects carcinogenesis and how chemotherapy works on it. Extrinsic and intrinsic routes, among other processes involved in apoptotic cell death, are clarified, emphasizing important molecular participants including caspases, the Bcl-2 family, and death receptors. The ubiquitin/proteasome system and methods for controlling apoptotic proteins, including as p53 and NF-κB, are also discussed in the study. It also covers specific methods of inducing apoptosis, such focusing on caspases and the Bcl-2 family, in addition to using TNF, TRAIL, and p53-based treatments. The study also offers insights into the state of preclinical and clinical research in apoptotic cancer treatment, as well as the assessment of new chemotherapeutic drugs that target different apoptotic pathways. All things considered, this review article provides insightful information on the many approaches and possible targets for boosting apoptotic cell death in cancer therapy, opening the door for the creation of more powerful therapeutic approaches.

Keywords: *Cancer therapy, apoptotic cell death, chemotherapeutic strategies, carcinogenesis*

***Corresponding Author**
Nagendra Singh
Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, 250001, U.P., India
Email: ns739527@gmail.com

1. INTRODUCTION

Gigantic exploration endeavors into major flagging pathways associated with cell development and demise are yielding malignant growth meds that are decisively focused on [1]. Various new natural specialists and little mixtures being developed objective apoptotic pathways [2]. The overflow of reagents and examines that give particularity in recognition has made the most common way of deciding the sub-atomic systems that administer and cause apoptotic demise charming and rousing [3]. Due to some degree to the difficulties related in estimating them, research on elective types of cell demise has limped along [4]. It's very much acknowledged information that chemotherapies just objective demise through apoptotic processes [5]. There is developing proof that the reaction of growth cells to chemotherapy includes something other than apoptosis; they may likewise go through extra types of death [6]. We investigate the ongoing comprehension of robotically characterized cell demise results in the principal piece of this survey, zeroing in on their capability in chemotherapeutic reaction and carcinogenesis [7]. The situation with creative chemotherapeutic medications that target atoms engaged with motioning of different cell demise pathways is analyzed in the subsequent part [8].

1.1. Cell Death Processes

There are four sorts of dynamic cell movement that have been distinguished that outcome in cell passing: corruption, autophagy, apoptosis, and mitotic disaster [9]. With regards to disease treatment, extremely durable development capture, usually alluded to as senescence, is likewise viewed as a sort of cell demise [10]. In view of extraordinary biochemical and actual qualities found in the perishing cell, these five classes of cell demise are

made (Table 1). Apoptosis and autophagy are two of these cycles that are believed to be "modified," alluding to their rigid hereditary guideline [11]. As an outcome of modified cell demise, constituent pieces of the phone separate and are consumed by adjoining cells [12]. In multicellular eukaryotic creatures, tissue remolding exercises all through ordinary advancement rely upon customized cell demise to add to the arrangement of the grown-up species [13]. In mature creatures, they likewise capability to safeguard solid cell tissue [14]. Mitotic disaster and putrefaction, all things considered, are viewed as detached responses to serious cell injury. New exploration, nonetheless, shows that a few kinds of mortality might actually be controlled by hereditary qualities [15]. Senescence, a pivotal part of maturing, is welcomed on by a quality coordinated program that incorporates telomere corruption and the enactment of flagging pathways engaged with cancer concealment. Tumorigenesis has been connected to dysregulation of the flagging pathways that manage every one of these sorts of cell passing. There are a few cell demise models that contrast from the ongoing meanings of the fundamental cell passing courses referenced above concerning morphology and organic chemistry [16]. These models incorporate postponed cell passing, necroptosis, paraptosis, pyroptosis, and caspase-autonomous apoptosis [17]. Just the five most all around depicted cell demise results — apoptosis, corruption, autophagy, mitotic disaster, and senescence — are remembered for this conversation with an end goal to keep things straightforward [18]. It's likewise essential to recall that, in a new endeavor, the editors of Cell Demise and Separation recommended describing cell passing just as far as the specific boundaries used to survey it, as opposed to as far as additional conventional words that characterize the expected cell demise system included [19].

Table 1: Characteristics of the cell death pathway [20]

Aspect	Apoptosis	Autophagy	Necrosis	Senescence	Mitotic catastrophe	Morphologic changes
Cell membrane	Maintaining membrane integrity in the face of blebbing	Blebbing	membrane integrity loss	flattening and enlarging of cells		
Nucleus	nuclear fragmentation, DNA laddering, and chromatin condensation	DNA laddering absent, partial condensation of chromatin	DNA deterioration at random	Focuses of heterochromatin growing up	chromosomal mis segregation during cytokinesis; micronuclei	
Cytoplasm	fragments of cells confined by membranes; depolymerization of the cytoskeleton	Degradation of endoplasmic reticulum (ER), autophagic vesicles, polyribosomes, and the Golgi	Cellular organelle swelling	Granularity		
Detection methods	Caspases activation, DNA fragmentation tests, and Annexin V staining	Localization of LC3	Early intracellular content release and permeability to critical dyes	Activity of β-galactosidase linked with senescence	Multinucleated cell visualization	Cellular contents released
Immunologic response	suppressive, cell carcass engulfment		stimulating, starting the process of tissue healing and cell proliferation			

1.2. Apoptosis

"Apoptosis" was first utilized in 1972 by Kerr, Wyllie, and Currie to recognize necrotic cell passing coming about because of intense tissue harm and normally happening ring formative cell demise, notwithstanding the reality the cycle had been reported for than a long period [21]. They likewise saw that apoptosis intervened the harmony between cell demise and development, which kept tissues in a homeostasis [22]. Apoptosis is described by morphologic changes, for example, nucleosomal fracture, chromatin buildup, cell shrinkage, and layer blebbing. Under typical circumstances, adjoining cells, known as macrophages, recognize apoptotic cells and eat their

divided carcasses. Various preclinical medication improvement concentrates on focus on the components controlling apoptosis, which is believed to be a vital system of chemotherapy-incited cell passing [23].

There are two distinct molecular signaling routes that lead to apoptotic cell death: the extracellularly enacted route and the inborn, mitochondria-interceded framework [24]. Virus infection, oncogene activation, and intracellular pressure signals including DNA damage and increased reactive oxygen species (ROS) often initiate the intrinsic course. To initiate the extracellular pathway, an agonist from outside the cell binds to a specific receptor on the plasma membrane. The rapid breakdown of cellular architecture and organelles is aided by proteolytic molecules called caspases, which are produced in response to the two pathways [25]. Proteins belonging to the caspase family have a nucleophilic cysteine accumulation that directs the cleavage of aspartic acid-containing themes. Caspases are transmitted as dormant precursors that, if cleavage mechanisms are initiated, transform into active oligomers [26]. There are two groups of caspases: those that serve as effectors or killers (caspases 3, 6, and 7) and those that act as initiators or apicals (caspases 8, 9, and 10). According to the research, initiator caspases may operate in a sequential fashion, but effector caspases need cleavage of initiator caspases to activate them.

2. THE EXTRINSIC PATHWAY: FAS

The Fas receptor serves as the focal point of the extrinsic route, which is comprised of a complex network of protein components that are essential for the beginning of the apoptotic process [27]. The essential components of this route include the caspases 8 and 10, as well as the Fas ligand (FasL), death receptors (DRs), Fas complexes, and the Fas-related death domain. Other components, such as DR3, Apo 2, DR4, DR5, and DR6 (TRAIL R1), also participate to the activation process, which is normally started by the interaction of death receptors on cell surfaces, such as Fas [28]. This route is often connected with cancer and immunological diseases, and it is essential for immune surveillance and the elimination of aberrant cells. Disruptions in this pathway are necessary for immune surveillance. The death-inducing signaling complex is formed as a result of the interaction between the film-bound FasL and the dormant Fas complexes, which is the next step in the cascade. Caspases 8 and 10, in conjunction with Fas-related death domain protein, are responsible for activating caspase 8, which acts as a crucial initiator for caspases that are located farther down the cascade [29]. At the same time as the cleavage of Bid by caspase 8 results in the release of cytochrome-c and apoptosis in some cell types, the activation of caspase 8 is sufficient for the triggering of cell death in other cell types [30]. A variety of regulatory mechanisms are put into action in order to avoid an excessive activation of the pathway. One example of these is the transcriptional regulators NF-κB and activating protein 1, which are responsible for controlling the expression of FasL. In addition, pathway inhibitors including FAP-1 and Fas-related death domain protein, as well as decoy receptors like DcR3, TRAIL R-3/DcR1, and TRAIL R-4/DcR2, compete with FasL, which means that they effectively attenuate Fas signaling.



Figure1: Extrinsic and Intrinsic Pathway [31]

2.1. The Intrinsic Pathway

Members of the Bcl-2 family are essential in controlling the release of apoptogenic proteins from mitochondria within the intrinsic route of apoptosis. One to four BH domains are present in these proteins, which affect whether they promote or prevent apoptosis. All four BH domains are present in antiapoptotic versions like Bcl-2, Bcl-xL, Mcl-1, Bcl-w, and Bf1-1/A1. On the other hand, proapoptotic members that do not include the BH4 domain are classified as "BH3-only" proteins and multidomain BH1-3 proteins like Bax and Bak [32].

"BH3-only" proteins and multidomain BH1-3 proteins like as Bax and Bak do not have BH4 domains, which might trigger upstream apoptotic processes, including mitochondrial outer membrane permeabilization (MOMP). When they oligomerize, Bak, which is confined in the outer layer of the mitochondria, and Bax, which is either found in the cytoplasm or linked to intracellular membranes, are crucial for inducing MOMP. Apoptogenic factors such cytochrome c, Omi/HtrA2, and Smac/DIABLO are released from the mitochondria during this phase.

Apaf-1 engages caspase-9 for activation when cytochrome c is released. This starts a caspase cascade that quickly cleaves intracellular substrates like caspase-3 and caspase-7. Proteins known as inhibitors of apoptosis (IAP) such as XIAP, c-IAP1, and c-IAP2, which bind and control caspase activity, influence the activity of these downstream effectors.

One of the main roles of antiapoptotic Bcl-2 proteins is to inhibit MOMP; this is done by preventing Bax and Bak oligomerization or BH3-only protein interactions. BH3-only proteins, including Puma, Noxa, Bid, Bad, Bim, and Bmf, may either trigger or reverse the effects of antiapoptotic Bcl-2 family members, while normally displaying proapoptotic effects [33].

Moreover, p53-related signaling pathways or post-translational changes control the proapoptotic actions of BH3-only proteins. The transcriptional activation of genes such as Bax, Puma, Noxa, and Bid, as well as the direct control of Bax and Bak dimerization, result in the activation of p53 in response to DNA damage, which in turn promotes MOMP and apoptosis.

2.2. Necrosis

Rot is now seen as a planned event that interacts with several developmental, physiological, and psychological circumstances; it has previously been described as an uncontrolled and obsessive kind of cell death [34]. Dysfunction of homeostatic particle siphons and channels, damage to layer lipids, and depletion of cellular energy are all components. Inhibition of cellular energy production, aberrant intracellular calcium transition, aging reactive oxygen species (ROS), and induction of nonapoptotic proteases are the triggers for rot. Loss of cellular capacity and corruption result from ATP depletion. mPT and putrefaction are both caused by the depolarization of the mitochondrial inner film. The PT pore component cyclophilin D (CypD) is anticipated to be involved in mPT and the subsequent corruption. Corrupting factors include oxidative stress, damage to intracellular atoms and organelles, and excessive ROS production. Among the several rot inducers, intracellular Ca2+ over-burden stands out as the most prominent example of "modified rot."

2.3. Autophagy

Every eukaryotic cell, from yeast to warm-blooded organisms, undergoes autophagy, a flexible cycle that is activated by nutritional deprivation, cell division, and developmental signals. It causes organelles and intracellular proteins to degrade [35]. Autophagy improves cell diversity and endurance in the face of stressors like famine and occurs at baseline levels in several tissues. Autophagy initiation, autophagosome maturation, extension, lysosome integration, and autophagosome content recycling are all regulated by a set of autophagy-related characteristics (ATG) in yeast. A link between impaired autophagy and cancer has been shown for Beclin 1, the mammalian equivalent of yeast Atg6. One haplotype that has been suggested to contribute to sufficient cancer silencer quality is Beclin 1, which is anticipated to have a role in autophagosome formation. Recent findings suggest that the outcome of the autophagic response might vary depending on the kind of insulin or cell stress.

2.4. Mitotic Catastrophe

Mitotic catastrophe, a consequence of mishandling chromosomes during sister chromatid separation, is characterized by abnormal mitosis, often considered an irrevocable precursor to cell demise rather than an endpoint in itself [36]. Eukaryotic cells are equipped with sophisticated surveillance systems that scrutinize chromosome integrity, triggering various signaling pathways upon detecting DNA damage. This may entail the activation of DNA repair mechanisms or the imposition of cell cycle checkpoints to restrain progression. In cases of severe damage, cells may undergo senescence or succumb to programmed cell death.

Recent studies propose that mitotic catastrophe arises from inadequacies in designated sites crucial for proper cell cycle progression, particularly the DNA structure checkpoint and spindle assembly checkpoint [37]. The failure to ensure accurate chromosome segregation and the generation of genetically identical daughter cells can precipitate mitotic catastrophe. Mis-segregation of multiple chromosomes can expedite cell death, leading to the emergence of giant cells with two nuclei or multiple micronuclei, often accompanied by binucleation and failure of cytokinesis.

Chemotherapeutic agents, by inducing damage to microtubules, can precipitate mitotic catastrophe, particularly in cancer cells lacking robust cell cycle checkpoint mechanisms. The inability to trigger mitotic catastrophe effectively may thus contribute to carcinogenesis, underscoring its significance in cancer therapy.

3. APOPTOTIC PROTEIN REGULATION

Proteins like the NFKB, the ubiquitin proteosome framework, and the PI3K pathway control both the inborn and outward apoptotic pathways (Figure 2). Because of their significance to the new prescriptions remembered for this survey, a short portrayal of them will be given [38].

- **p53**

As a record factor, p53 controls qualities that are downstream of cell cycle capture, DNA fix, and apoptosis. The way that such countless growths have p53 quality changes is demonstrative of the critical capability that this quality plays. In a few malignancies, p53 misfortune results in genomic shakiness, compromised control of the cell cycle, and concealment of apoptosis. p53 keeps the cell at a designated spot after DNA harm until the harm is fixed. Apoptosis is actuated in situations when the damage is extremely durable. The specific strategy by means of which p53 advances apoptosis is yet obscure.

- **NFκB**

FKB is an atomic record factor that controls the declaration of a few qualities engaged with the control of irritation, disease, viral replication, apoptosis, and various immune system disorders.25Numerous improvements, for example, development factors, cytokines, lymphokines, radiation, drug medications, and stress, may enact NFKB [39]. IKB family inhibitor proteins are limited by NFKB in its lethargic state, which is bound in the cytoplasm. IKB is phosphorylated by the few improvements that enact NFKB, and this is trailed by its obliteration. As a result, the NFKB subunits' atomic confinement signals are uncovered, and the particle is then moved to the core. NFKB ties to the agreement successions of various qualities in the core, enacting the record of those qualities.

It has been shown that NFKB has both supportive of and hostile to apoptotic properties, which still up in the air by the sort of death boosts as opposed to the tissue's place of origin.26Under physiological settings, TNF receptor-related factor, IAP, and X-connected IAP are a couple of the perplexing proteins that are enacted when NFKB is actuated. This outcomes in protection from apoptotic improvements. Nonetheless, NFKB enactment might make apoptosis be actuated in light of specific stimuli.26The enactment of some proapoptotic proteins, including p53, c-myc, interferon-managed factor-1, and caspases like caspase 1, could represent this. In a few viral contaminations, the infection's capacity to prompt apoptosis relies upon the enactment of NFKB.



Figure 2: The apopototic routes, both internal and external. The PI3K pathway, NFKB, ubiquitin/proteosome framework, and p53 are proteins that regulate them. Apoptosis Pathway Specialized in Cancer Treatment 182CAA Disease Journal for Medical Professionals [40].

4. THE UBIQUITIN/PROTEOSOME SYSTEM

In order to govern cell development and avert cell death, the ubiquitin/proteasome system is essential for controlling protein turnover within the cell. This system, which consists of a large proteinase complex made up of proteasomes and ubiquitin, is responsible for coordinating the breakdown of a wide range of cellular constituents and regulatory proteins. The 26S proteasome carefully carries out the process of protein breakdown, which is started when ubiquitin molecules attach to target proteins [41].

The ubiquitin/proteasome system controls a number of factors that affect the cell cycle and gene expression, such as proteins like p53, NF-κB, cyclins, and cyclin-dependent kinase inhibitors. To further emphasize this complex's wide regulatory range, several Bcl-2 family members act as substrates for it.

By activating proteins like p53, p27, and proapoptotic factors like Bad or Bax, or by triggering stress kinase activation, which results in cytochrome-c release and the start of the apoptotic pathway, inhibition of the ubiquitin/proteasome system may cause apoptosis [42]. Interest in creating tailored inhibitors to alter these pathways for therapeutic reasons has increased because of the crucial interaction between the ubiquitin/proteasome system and the apoptotic apparatus.

5. FOCUSED METHODS FOR INDUCING CELL DEATH

Hereditary alterations to cell death signaling pathways contribute to carcinogenesis, according to a fundamental principle of disease research. Chemotherapeutic drugs are effective because they kill cancer cells, which is a strange fact in clinical oncology [43]. In the absence of potent cell death mechanisms, what do these experts do? Common chemo drugs trap normal, untransformed cells in the cell cycle, fix their DNA, or even kill them in extreme circumstances. Solid p53 flagging is the primary need for this tool. Mutations or abnormalities in p53 signaling constitute the etiology of the vast majority of human cancers. Alterations to the Bcl2 family are also common. Substance misuse has been influenced by the role of p53, the Bcl-2 family, and other apoptosis-promoting particles. As a result of some of these initiatives, novel medicines are now undergoing clinical preliminary trials. Underneath, we discuss these drugs and others that are thought to target chemicals that might cause cell death in addition to apoptosis.

- **Activating Apoptosis**
- **Bcl-2 Family**

Bcl-2, Bcl-xL, A1, and Mcl-1 are antiapoptotic Bcl-2 cousins that are often present in several cell types; their amplification helps overcome chemotherapeutic resistance. Several approaches to address the issue of these antiapoptotic proteins are now under investigation. First, there are oligonucleotides that can be used to reduce articulation; second, there are peptides that can be used to discourage security by including just BH3 or Bax articulation; and third, there are small mixes that can be used to prevent defensive associations [44]. One medicine that is now leading clinical trials is Obilemersen, a nuclease-safe antisense oligonucleotide that targets Bcl-2 mRNA (Gena sense Genta Inc., Berekeley Levels, NJ). In phase II and III clinical trials, oblimersen is being used to treat a variety of malignancies in both children and adults. This kind of melanoma was not approved for oblomersen treatment because results from the stage III evaluation failed to show that the drug increased endurance. However, oblimersen with docetaxel worked well in treating chemically resistant prostate cancer.

Table 2: Certain chemotherapeutic drugs that target the processes leading to cell death [45]

Death Pathway	Protein Classification	Chemotherapeutic Agent	Target	Type of Compound	Sponsoring Organization	Stage
Apoptosis	Bcl-2	Oblimersen	Bcl-2	Antisense oligonucleotide	Genta/Aventis	Phase II/III
Apoptosis	SAHBs	Bcl-2 family	Peptidomimetic	Harvard University	Preclinical	
Apoptosis	ABT-737	Bcl-2/Bcl-xL	Small compound	Abbott	Preclinical	
Apoptosis	Gossypol	Bcl-2	Small compound	NCI/Ascenta	Phase I	
Apoptosis	IAP Compound 3	IAPs	Small compound	University of Texas Southwestern	Preclinical	
Apoptosis	AEG 35156/GEM640	XIAP	Antisense oligonucleotide	Aegera/Hybridon	Phase I (outside U.S.)	
Apoptosis	Polyphenylureas	XIAP/caspase-3, -7	Small compound	The Burnham Institute	Preclinical	
Apoptosis	p53 Nutlins	p53/MDM2	Small compound	Hoffman-La Roche	Preclinical	

Death Receptors	TRAIL	DR4/DR5	Recombinant protein	Genentech/Amgen	Phase I	
Death Receptors	HGS-ETR1	DR4	Agonistic mAb	Human Genome Sciences	Phase II	
Death Receptors	HGS-ETR2	DR5	Agonistic mAb	Human Genome Sciences	Phase II	
Death Receptors	TNF-α	TNFR	Recombinant protein	FDA approved, limb perfusion	-	-
Death Receptors	CDDO	FLIP	Small compound	Dartmouth College/Reata	Preclinical	
Necrosis	PDT	Metabolism, ROS, Ca2+	Clinical	-	-	-
Necrosis	PARP	DNA alkylating agents	DNA damage, metabolism	Clinical	-	-
Necrosis	β-Lapachone	Metabolism, ROS, Ca2+	Natural compound	-	-	Preclinical
Mitotic Catastrophe	Mitosis	SB-715992	KSP/Eg5	Small compound	Cytokinetics/GSK	Phase II
Mitotic Catastrophe	Mitosis	UCN-01	Chk1	Small compound	NCI	Phase I/II
Mitotic Catastrophe	Mitosis	CEP-3891	Chk1	Small compound	Cephalon	Preclinical
Mitotic Catastrophe	Mitosis	SB-218078	Chk1	Small compound	GSK	Preclinical
Mitotic Catastrophe	Mitosis	A-641397	Chk1	Small compound	Abbott	Preclinical
Senescence	Telomerase	GRN163L	hTR	Antisense oligonucleotide	-	Preclinical

- **Caspases**

An further intriguing method for concentrating on apoptosis is the enhancement of Smac/DIABLO copies to prevent IAP from being limited to caspases. Although peptides containing the Smac/DIABLO IAP restriction motif have been synthesized, their rapid in vivo degradation limits their potential therapeutic use. A peptidomimetic, which is a synthetic version of an amino acid, was an ingenious solution to this problem.

Compound 3 is a peptidomimetic with strong binding affinity for all three IAP proteins. Compound 3 was shown to induce glioblastoma cell death in vitro when combined with TRAIL. A small number of pharmaceutical combinations have shown remarkable promise in preclinical studies by mimicking the Smac/DIABLO restriction area.

These newly mentioned experts were transformed into Smac-like entities limited to the XIAP BIR3 region. In the end, a clear strategy was developed to block caspase 3 and 7 XIAP barriers via their BIR2 space. A chemical screen revealed that some polyphenylureas were very effective in inducing cell death, regardless of whether the cells lacked bax or bak or had Bcl-2/xL overexpression. Phase I trials for a third approach, antisense to XIAP (AEG35156/GEM640), both alone and in combination with docetaxel, have just started (with preliminary results expected in the UK and Canada soon).

In addition, the possibility of treating diseases by direct caspase activation has been considered. The use of adenoviral vectors is to prevent the intended cell from undergoing caspase enactment. A genetically engineered caspase-9 variant known as iCaspase-9 is one example; it is driven by an androgen-specific, prostate-specific promoter and is exclusive to growing xenografts. Apoptosis and caspase-9 autoproteolysis occur throughout the actuating prescription process. Similarly, to pinpoint the vasculature, a vascular endothelial growth factor receptor 2 advertisement was used to regulate iCaspase9 in endothelial cells. Medication infusions directly destroyed the growing vasculature.

- **TNF**

TNF ligands have drawn a ton of interest as go betweens of disease cell passing since TNF was found. TNF and FasL might make disease cells go through apoptosis, yet their utility in fundamental anticancer therapy is restricted by their extremely deadly aftereffects. At the point when individuals were given TNF fundamentally, they had a provocative reaction like septic shock. In preclinical mice, agonistic enemies of Fas antibodies or FasL prompted lethal liver harm. Nonetheless, in 1998, recombinant TNF was approved in Europe for use in separated appendage perfusion treatment for the treatment of sarcomas. When used for limited treatment of sarcomas and melanomas,

TNF in mix with chemotherapeutic medications, for example, melphalan, shows selectivity for disposal of growth vasculature and is extremely viable. After stage III clinical examinations, TNF with melphalan is forthcoming freedom for utilization in the US.

- **TRAIL**

At the point when given foundationally to mice and nonhuman primates, recombinant human Path displayed no poisonousness, as opposed to TNF or FasL. In both cancer inserts in seriously joined immunodeficient mice and an assortment of growth cells in culture, recombinant human Path might prompt apoptosis. Stage I/II examinations are under in progress for recombinant Path and enacting DR4 and DR5 antibodies. Numerous disease cells are impervious to TRAIL-actuated apoptosis, similar as most of ordinary cells. TRAIL, be that as it may, may work working together with various customary and creative specialists. Both in vitro and in vivo, safe cells were made powerless to TRAIL by chemotherapy or radiation. Various cytotoxic chemotherapy drugs create cell stressors and harm to DNA, which balances out the p53 growth silencer protein. Proapoptotic proteins, for example, DR5 and others are transcriptionally actuated by p53 and work working together with TRAIL. Thus, involving TRAIL related to these medications should function admirably as a therapy approach for tumors that have working p53.
The capacity of death receptor motioning toward happen without working p53 is a fascinating part of this cycle. Right now going through clinical preliminaries, inhibitors of histone deacetylases (HDACIs) can cause apoptosis in disease cells. One impact of HDACIs is that they make intense myeloid leukemia cells go through particular apoptosis by upregulating the development of TRAIL. The creation of many Path flagging related proteins is upgraded by HDACIs, including DR5. When combined with TRAIL, these proteins might sharpen TRAIL-safe cells. In addition, IFN-γ and glucocorticoids likewise raise DR5 articulation, which could further develop TRAIL action. Obliterensen has been displayed to sharpen a Fas-and INF-γ-safe kidney disease cell line to INF-γ in mix with a Fas-enacting immune response, despite the fact that there are no distributed distributions looking at its preclinical use related to TRAIL.

- **p53**

Therapeutic strategies targeted at restoring wild-type p53 signaling in cancer cells are the main focus of ongoing clinical studies. An immune response directed against cancer cells with p53 mutations is being worked on. Adenoviral vectors expressing wild-type p53 are one tactic that is being tested in several cancer studies. These vectors may be delivered directly into tumors, either alone or in conjunction with ionizing radiation (IR) or other traditional DNA-damaging agents [46].
Furthermore, studies are looking at using peptides or tiny compounds to help mutant p53 regain its ability to bind DNA. Mutant p53 is commonly overexpressed in malignancies because it usually loses the capacity to bind regulators such as MDM2 (mouse double minute 2). In an attempt to restore DNA binding in mutant p53, substances like Prima-1 and CP-31398 have been studied; however, it is unclear whether they will ever be put through clinical testing.
An alternative strategy is regaining wild-type p53 activity by interfering with p53's connections with proteins that aid in its destruction. Nutlins are a class of tiny compounds that have the potential to repair p53 function by blocking MDM2's capacity to break it down. These developments in p53-targeted therapeutics merit further study in clinical settings and provide promising options for improving cancer therapy results.

Table 3: Therapies for Cell Death

Author	Subject	Results
Carneiro & El-Deiry (2020) [47]	Apoptosis targeting in cancer treatment	investigates the mechanisms of apoptosis in cancer, the role of deregulation in carcinogenesis, and resistance.
Jan (2019) [48]	Apoptosis in the treatment of cancer	examines apoptotic mechanisms in cancer and talks about treatment options and potential developments.
Qi et al. (2022) [49]	Regulatory cell death in treatments for cancer	examines the mechanisms of regulatory cell death, their function in the tumor microenvironment, and the effectiveness of treatment.
Peng et al. (2022) [50]	In cancer, regulated cell death (RCD)	discusses the several RCDs (apoptosis, necroptosis, ferroptosis, and pyroptosis) that are used in cancer treatment.
Rapoport & Anderson (2019) [51]	Immunogenic cell death with radiation and chemotherapy for cancer	examines mechanisms and potential future possibilities while concentrating on using ICD to increase the effectiveness of cancer treatment.

Due to its inability to bind to regulators like MDM2, the human analogue of mouse double minute 2, mutant p53 is typically overexpressed in cancers, in contrast to wild-type p53. It is uncertain if the first two tiny molecules discovered to restore DNA binding to p53 mutations—CP-31398 and Prima-1—will undergo clinical testing. One other approach is to restore wild-type p53 function by disrupting the interactions between p53 and the proteins

that promote its degradation. A family of small chemicals called nutlins may restore p53 function by blocking MDM2's capacity to destroy it [52].

6. CONCLUSION

In conclusion, a viable strategy for enhancing patient outcomes from cancer therapy is to target apoptotic cell death. By clarifying the complex mechanisms underlying apoptosis and the dysregulations that lead to cancer, scientists have found a wide range of molecular targets that might be targeted with therapeutic intervention [53]. Apoptotic cancer treatment is complex, as seen by the variety of approaches included in this review, which range from directly triggering apoptotic pathways to modifying upstream regulators such as NF-κB and p53. Additionally, the investigation of new chemotherapeutic drugs that target apoptotic pathways highlights the continuous attempts to provide less harmful and more effective therapies [54]. There is optimism for the area to advance for preclinical discoveries to be translated into clinically significant outcomes via clinical studies testing these drugs. All things considered, a thorough grasp of the processes behind apoptotic cell death and the creation of focused therapeutic methods show promise for raising patient survival rates and the effectiveness of cancer treatments [55]. Realizing the full potential of apoptotic cancer treatment in the battle against cancer will need ongoing investigation into apoptotic pathways and the use of these discoveries in clinical settings.

REFERENCE

1. Asadzadeh, Z., Safarzadeh, E., Safaei, S., Baradaran, A., Mohammadi, A., Hajiasgharzadeh, K., ... & Baradaran, B. (2020). Current approaches for combination therapy of cancer: the role of immunogenic cell death. *Cancers*, *12*(4), 1047.
2. Boice, A., & Bouchier-Hayes, L. (2020). Targeting apoptotic caspases in cancer. *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research*, *1867*(6), 118688.
3. Fucikova, J., Kepp, O., Kasikova, L., Petroni, G., Yamazaki, T., Liu, P., ... & Galluzzi, L. (2020). Detection of immunogenic cell death and its relevance for cancer therapy. *Cell death & disease*, *11*(11), 1013.
4. Pfeffer, C. M., & Singh, A. T. (2018). Apoptosis: a target for anticancer therapy. *International journal of molecular sciences*, *19*(2), 448.
5. Tong, X., Tang, R., Xiao, M., Xu, J., Wang, W., Zhang, B., ... & Shi, S. (2022). Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. *Journal of hematology & oncology*, *15*(1), 174.
6. Zhou, J., Wang, G., Chen, Y., Wang, H., Hua, Y., & Cai, Z. (2019). Immunogenic cell death in cancer therapy: Present and emerging inducers. *Journal of cellular and molecular medicine*, *23*(8), 4854-4865.
7. Shojaei, S., Koleini, N., Samiei, E., Aghaei, M., Cole, L. K., Alizadeh, J., ... & Ghavami, S. (2020). Simvastatin increases temozolomide-induced cell death by targeting the fusion of autophagosomes and lysosomes. *The FEBS journal*, *287*(5), 1005-1034.
8. Wang, Q., Ju, X., Wang, J., Fan, Y., Ren, M., & Zhang, H. (2018). Immunogenic cell death in anticancer chemotherapy and its impact on clinical studies. *Cancer letters*, *438*, 17-23.
9. Ahmed, A., & Tait, S. W. (2020). Targeting immunogenic cell death in cancer. *Molecular oncology*, *14*(12), 2994-3006.
10. Lv, H., Zhen, C., Liu, J., Yang, P., Hu, L., & Shang, P. (2019). Unraveling the potential role of glutathione in multiple forms of cell death in cancer therapy. *Oxidative medicine and cellular longevity*, *2019*.
11. Bhutia, S. K., Panda, P. K., Sinha, N., Praharaj, P. P., Bhol, C. S., Panigrahi, D. P., ... & Maiti, T. K. (2019). Plant lectins in cancer therapeutics: Targeting apoptosis and autophagy-dependent cell death. *Pharmacological research*, *144*, 8-18.
12. Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021). Nanomaterials for cancer therapy: current progress and perspectives. *Journal of hematology & oncology*, *14*, 1-27.
13. Alimbetov, D., Askarova, S., Umbayev, B., Davis, T., & Kipling, D. (2018). Pharmacological targeting of cell cycle, apoptotic and cell adhesion signaling pathways implicated in chemoresistance of cancer cells. *International journal of molecular sciences*, *19*(6), 1690.
14. Gong, Y., Fan, Z., Luo, G., Yang, C., Huang, Q., Fan, K., ... & Liu, C. (2019). The role of necroptosis in cancer biology and therapy. *Molecular cancer*, *18*, 1-17.
15. Zhang, C., Liu, X., Jin, S., Chen, Y., & Guo, R. (2022). Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. *Molecular cancer*, *21*(1), 47.

16. Mishra, A. P., Salehi, B., Sharifi-Rad, M., Pezzani, R., Kobarfard, F., Sharifi-Rad, J., & Nigam, M. (2018). Programmed cell death, from a cancer perspective: an overview. *Molecular diagnosis & therapy*, *22*, 281-295.
17. Ye, J., Zhang, R., Wu, F., Zhai, L., Wang, K., Xiao, M., ... & Sui, X. (2018). Non-apoptotic cell death in malignant tumor cells and natural compounds. *Cancer letters*, *420*, 210-227.
18. Wu, D., Wang, S., Yu, G., & Chen, X. (2021). Cell death mediated by the pyroptosis pathway with the aid of nanotechnology: prospects for cancer therapy. *Angewandte Chemie*, *133*(15), 8096-8112.
19. Cordani, M., & Somoza, Á. (2019). Targeting autophagy using metallic nanoparticles: A promising strategy for cancer treatment. *Cellular and molecular life sciences*, *76*, 1215-1242.
20. Liu, Y. P., Zheng, C. C., Huang, Y. N., He, M. L., Xu, W. W., & Li, B. (2021). Molecular mechanisms of chemo-and radiotherapy resistance and the potential implications for cancer treatment. *MedComm*, *2*(3), 315-340.
21. Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., ... & de la Lastra, J. M. P. (2022). Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. *Genes & Diseases*.
22. Hsu, S. K., Li, C. Y., Lin, I. L., Syue, W. J., Chen, Y. F., Cheng, K. C., ... & Chiu, C. C. (2021). Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. *Theranostics*, *11*(18), 8813.
23. Bukowski, K., Kciuk, M., & Kontek, R. (2020). Mechanisms of multidrug resistance in cancer chemotherapy. *International journal of molecular sciences*, *21*(9), 3233.
24. Lu, C., Li, X., Ren, Y., & Zhang, X. (2021). Disulfiram: a novel repurposed drug for cancer therapy. *Cancer chemotherapy and pharmacology*, *87*, 159-172.
25. Hashem, S., Ali, T. A., Akhtar, S., Nisar, S., Sageena, G., Ali, S., ... & Bhat, A. A. (2022). Targeting cancer signaling pathways by natural products: Exploring promising anti-cancer agents. *Biomedicine & Pharmacotherapy*, *150*, 113054.
26. Bykov, V. J., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018). Targeting mutant p53 for efficient cancer therapy. *Nature Reviews Cancer*, *18*(2), 89-102.
27. Mishchenko, T., Balalaeva, I., Gorokhova, A., Vedunova, M., & Krysko, D. V. (2022). Which cell death modality wins the contest for photodynamic therapy of cancer?. *Cell death & disease*, *13*(5), 455."
28. Thakkar, S., Sharma, D., Kalia, K., & Tekade, R. K. (2020). Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review. *Acta biomaterialia*, *101*, 43-68.'
29. Diepstraten, S. T., Anderson, M. A., Czabotar, P. E., Lessene, G., Strasser, A., & Kelly, G. L. (2022). The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs. *Nature Reviews Cancer*, *22*(1), 45-64.
30. Denisenko, T. V., Budkevich, I. N., & Zhivotovsky, B. (2018). Cell death-based treatment of lung adenocarcinoma. *Cell death & disease*, *9*(2), 117.
31. Alzeibak, R., Mishchenko, T. A., Shilyagina, N. Y., Balalaeva, I. V., Vedunova, M. V., & Krysko, D. V. (2021). Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. *Journal for immunotherapy of cancer*, *9*(1).
32. Chen, W. H., Luo, G. F., & Zhang, X. Z. (2019). Recent advances in subcellular targeted cancer therapy based on functional materials. *Advanced Materials*, *31*(3), 1802725.
33. Yang, H., Villani, R. M., Wang, H., Simpson, M. J., Roberts, M. S., Tang, M., & Liang, X. (2018). The role of cellular reactive oxygen species in cancer chemotherapy. *Journal of Experimental & Clinical Cancer Research*, *37*, 1-10.
34. Shteinfer-Kuzmine, A., Amsalem, Z., Arif, T., Zooravlov, A., & Shoshan-Barmatz, V. (2018). Selective induction of cancer cell death by VDAC 1-based peptides and their potential use in cancer therapy. *Molecular oncology*, *12*(7), 1077-1103.
35. Fabian, K. P., Wolfson, B., & Hodge, J. W. (2021). From immunogenic cell death to immunogenic modulation: select chemotherapy regimens induce a spectrum of immune-enhancing activities in the tumor microenvironment. *Frontiers in oncology*, *11*, 728018.
36. Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021). Cell death in pancreatic cancer: from pathogenesis to therapy. *Nature reviews Gastroenterology & hepatology*, *18*(11), 804-823.

37. Elgendy, S. M., Alyammahi, S. K., Alhamad, D. W., Abdin, S. M., & Omar, H. A. (2020). Ferroptosis: An emerging approach for targeting cancer stem cells and drug resistance. *Critical Reviews in Oncology/Hematology*, *155*, 103095.
38. Debela, D. T., Muzazu, S. G., Heraro, K. D., Ndalama, M. T., Mesele, B. W., Haile, D. C., ... & Manyazewal, T. (2021). New approaches and procedures for cancer treatment: Current perspectives. *SAGE open medicine*, *9*, 20503121211034366.
39. Kocaturk, N. M., Akkoc, Y., Kig, C., Bayraktar, O., Gozuacik, D., & Kutlu, O. (2019). Autophagy as a molecular target for cancer treatment. *European Journal of Pharmaceutical Sciences*, *134*, 116-137.
40. Abdel-Wahab, A. F., Mahmoud, W., & Al-Harizy, R. M. (2019). Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. *Pharmacological research*, *150*, 104511.
41. Čermák, V., Dostál, V., Jelínek, M., Libusová, L., Kovář, J., Rösel, D., & Brábek, J. (2020). Microtubule-targeting agents and their impact on cancer treatment. *European journal of cell biology*, *99*(4), 151075.
42. Rahman, M. A., Hannan, M. A., Dash, R., Rahman, M. H., Islam, R., Uddin, M. J., ... & Rhim, H. (2021). Phytochemicals as a complement to cancer chemotherapy: pharmacological modulation of the autophagy-apoptosis pathway. *Frontiers in Pharmacology*, *12*, 639628.
43. Koren, E., & Fuchs, Y. (2021). Modes of regulated cell death in cancer. *Cancer discovery*, *11*(2), 245-265.
44. Tan, Y., Chen, Q., Li, X., Zeng, Z., Xiong, W., Li, G., ... & Yi, M. (2021). Pyroptosis: a new paradigm of cell death for fighting against cancer. *Journal of Experimental & Clinical Cancer Research*, *40*(1), 153.
45. Sharma, A., Goyal, A. K., & Rath, G. (2018). Recent advances in metal nanoparticles in cancer therapy. *Journal of drug targeting*, *26*(8), 617-632.
46. Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020). Overcoming cancer therapeutic bottleneck by drug repurposing. *Signal transduction and targeted therapy*, *5*(1), 113.
47. Carneiro, B. A., & El-Deiry, W. S. (2020). Targeting apoptosis in cancer therapy. *Nature reviews Clinical oncology*, *17*(7), 395-417.
48. Jan, R. (2019). Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. *Advanced pharmaceutical bulletin*, *9*(2), 205.
49. Qi, X., Li, Q., Che, X., Wang, Q., & Wu, G. (2022). Application of regulatory cell death in cancer: based on targeted therapy and immunotherapy. *Frontiers in immunology*, *13*, 837293.
50. Peng, F., Liao, M., Qin, R., Zhu, S., Peng, C., Fu, L., ... & Han, B. (2022). Regulated cell death (RCD) in cancer: key pathways and targeted therapies. *Signal transduction and targeted therapy*, *7*(1), 286.
51. Rapoport, B. L., & Anderson, R. (2019). Realizing the clinical potential of immunogenic cell death in cancer chemotherapy and radiotherapy. *International journal of molecular sciences*, *20*(4), 959.
52. Suvarna, V., Singh, V., & Murahari, M. (2019). Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy. *European journal of pharmacology*, *862*, 172655.
53. Mou, Y., Wang, J., Wu, J., He, D., Zhang, C., Duan, C., & Li, B. (2019). Ferroptosis, a new form of cell death: opportunities and challenges in cancer. *Journal of hematology & oncology*, *12*, 1-16.
54. Çeşmeli, S., & Biray Avci, C. (2019). Application of titanium dioxide (TiO2) nanoparticles in cancer therapies. *Journal of drug targeting*, *27*(7), 762-766.
55. Sharifi, M., Hasan, A., Nanakali, N. M. Q., Salihi, A., Qadir, F. A., Muhammad, H. A., ... & Falahati, M. (2020). Combined chemo-magnetic field-photothermal breast cancer therapy based on porous magnetite nanospheres. *Scientific Reports*, *10*(1), 5925.

*****